Investors interested in Medical - Drugs stocks are likely familiar with Merck KGaA (MKKGY) and Stevanato Group (STVN) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positi ...

Stevanato Group (STVN) shares rallied 10% in the last trading session to close at $27.95. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.6% gain over the past four weeks.The sharp rise in Stevanato’s stock price likely reflects growing investor confidence in the company’s revenue outlook, particularly from its high-value solutions segment. Strong demand for high-value syringes, increased production capacit ...

Group 1 - The company Stevanato (NYSE: STVN) is rated with a Buy rating, indicating a positive outlook for the upcoming years [1] - A new facility in the U.S. is expected to generate significant revenue for the company [1] Group 2 - The analyst Daniel Mellado has a background in economics and statistics, with experience in analyzing agricultural commodities and managing trading and data analysis teams [1] - The trading team under his management invested in bonds, equities, and ETFs, showcasing a diverse investment strategy [1] - Future analysis and valuation will focus on sectors including commodities, banking, technology, and pharmaceuticals [1]

Group 1 - The Q1 results in Diversified Tools and Pharma Services showed modest outperformance despite multiple guidance revisions [1] - The revisions reflect a more challenging macroeconomic environment, including tariffs and NIH-related disruptions [1] - There is a more cautious stance on biopharma spending noted in the current analysis [1]

Stevanato Group (STVN) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 Jeff there we go. Hi. Good morning. Dave Windley with Jefferies Healthcare Equity Research. Appreciate your attendance and and interest in our conference twenty twenty five. We are on kind of the homestretch here on Thursday. Our presenting company for this session is Stevanato Group. Here to present for them is the company's CEO, Franco Sveinato. So he has just a few slides and is going to give some prepared remarks to kick off and t ...

Summary of Stevanato Group (STVN) FY Conference Call Company Overview - **Company**: Stevanato Group (STVN) - **Industry**: Pharmaceutical packaging and engineering solutions - **History**: Established over 75 years ago, originally focused on glass containers for various applications, now a leader in the pharmaceutical industry [5][6] Key Points and Arguments Market Position and Growth - Stevanato Group is a market leader in pen cartridges and ready-to-fill vials, and the second player in syringes globally [7] - The company has achieved a revenue growth of 15% per year over the last five years, doubling its revenue to €1.1 billion in 2024, with a focus on the pharmaceutical industry [8][38] - The addressable market for Stevanato is estimated at $13 billion per year, growing at high single-digit to low double-digit rates [22] Business Segments - The company operates two main business units: - **BDS Segment**: Represents over 80% of revenue, focusing on drug containment solutions and biologics [9][22] - **Engineering Segment**: Growing rapidly, with an addressable market of $1.5 billion [24] Investment and Capacity Expansion - Stevanato has invested over €1 billion post-IPO to increase capacity, particularly in Europe and the United States [19][45] - A significant investment of €500 million is being made in a greenfield plant outside Indianapolis, expected to generate €500 million in revenue by 2028 [20][47] - The company is focused on high-value products, with gross margins targeted between 40% to 70% [33] Technological Advancements - Stevanato has developed patented technologies such as EZFill for syringes and vials, enhancing value and security for clients [16] - The company has tech centers in Italy and Boston, employing 80 engineers to support clients from preclinical stages to FDA filing [11][21] Market Trends and Client Demand - The pharmaceutical industry is increasingly outsourcing non-core competencies, allowing Stevanato to provide services like washing, sterilization, and preassembly [16][31] - There is a robust pipeline of new drugs in phases II and III, with a focus on biologics and self-administration devices [27][61] - The demand for injectable drugs is expected to grow, countering concerns about the shift to oral medications [62][63] Financial Performance and Future Outlook - The company faced destocking issues related to COVID-19 but is now seeing a normalization in orders from clients [55][58] - Q1 2025 showed a positive growth of 9%, with expectations for continued growth throughout the year [41][42] - Stevanato aims to maintain a high single-digit to low double-digit growth rate in the coming years, supported by ongoing investments [45] Additional Important Insights - The company emphasizes a strong leadership team and board of directors with experience in the pharmaceutical and packaging industries [17] - Stevanato's strategy includes a focus on digitalization to enhance operational efficiency [53] - The company aims to be recognized as a proactive partner for its clients, focusing on high-value products and solid contracts [54] This summary encapsulates the key points discussed during the Stevanato Group FY conference call, highlighting the company's market position, growth strategies, technological advancements, and future outlook.

[Unaudited Interim Condensed Consolidated Financial Statements](index=7&type=section&id=Unaudited%20Interim%20Condensed%20Consolidated%20Financial%20Statements) This section presents the unaudited interim condensed consolidated financial statements, including the income statement, financial position, and cash flows for the period ended March 31, 2025 [Interim Consolidated Income Statement](index=7&type=section&id=Interim%20consolidated%20income%20statement) For the three months ended March 31, 2025, Stevanato Group reported revenue of €256.6 million, an 8.7% increase year-over-year, with net profit attributable to equity holders rising by 40.9% to €26.5 million Income Statement Highlights (Q1 2025 vs Q1 2024) | Metric | Q1 2025 (EUR million) | Q1 2024 (EUR million) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 256.6 | 236.0 | 8.7% | | Gross Profit | 69.9 | 62.2 | 12.4% | | Operating Profit | 34.6 | 25.3 | 36.9% | | Profit Before Tax | 35.1 | 25.7 | 36.7% | | Net Profit (attributable to parent) | 26.5 | 18.8 | 40.9% | | Diluted EPS (in EUR) | 0.10 | 0.07 | 42.9% | [Interim Consolidated Statement of Financial Position](index=9&type=section&id=Interim%20consolidated%20statement%20of%20financial%20position) As of March 31, 2025, the Group's total assets were €2.324 billion, a slight decrease from year-end 2024, while total equity increased to €1.416 billion, reflecting a stable financial position Statement of Financial Position (As of March 31, 2025) | Metric | March 31, 2025 (EUR million) | Dec 31, 2024 (EUR million) | | :--- | :--- | :--- | | Total Assets | 2,324.2 | 2,328.8 | | Total Liabilities | 908.3 | 924.4 | | Total Equity | 1,415.9 | 1,404.4 | [Interim Consolidated Statement of Cash Flows](index=12&type=section&id=Interim%20consolidated%20statements%20of%20cash%20flows) For the first three months of 2025, the Group generated €99.8 million in cash from operating activities, a significant increase from the prior year, while cash used in investing activities decreased Cash Flow Summary (Q1 2025 vs Q1 2024) | Metric | Q1 2025 (EUR million) | Q1 2024 (EUR million) | | :--- | :--- | :--- | | Net Cash Flows from operating activities | 99.8 | 71.6 | | Net Cash Flows used in investing activities | (70.7) | (102.1) | | Net Cash Flows (used in)/ from financing activities | (35.8) | 146.9 | | Net change in cash and cash equivalents | (6.6) | 116.3 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=51&type=section&id=Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's discussion and analysis of the company's financial condition, operational results, liquidity, and key non-GAAP performance indicators for the period [Overview](index=51&type=section&id=Overview) Stevanato Group is a global provider of integrated solutions for the pharmaceutical, biotech, and life sciences industries, expanding its global footprint while navigating market challenges - The company operates in two segments: Biopharmaceutical and Diagnostic Solutions (containment and delivery solutions) and Engineering (manufacturing equipment and technology)[167](index=167&type=chunk)[179](index=179&type=chunk) - The Group is expanding its global capacity for high-value solutions, with ongoing projects in Fishers, Indiana (U.S.) and Latina, Italy, where commercial production has started at both sites[23](index=23&type=chunk)[166](index=166&type=chunk) - The company is experiencing challenges from customer destocking of glass vials post-pandemic, temporary inefficiencies from new plant ramp-ups, and increased costs on certain delayed projects in its Denmark-based Engineering operations[170](index=170&type=chunk)[171](index=171&type=chunk)[173](index=173&type=chunk) [Results of Operations (Q1 2025 vs Q1 2024)](index=58&type=section&id=Results%20of%20Operations) In Q1 2025, revenue grew 8.7% to €256.6 million, driven by an 11.0% increase in the Biopharmaceutical and Diagnostic Solutions segment, particularly a 25.4% rise in high-value solutions Consolidated Results of Operations (Q1 2025 vs Q1 2024) | Metric | Q1 2025 (EUR million) | Q1 2024 (EUR million) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 256.6 | 236.0 | 8.7% | | Gross Profit | 69.9 | 62.2 | 12.4% | | Operating Profit | 34.6 | 25.3 | 36.9% | | Net Profit | 26.5 | 18.8 | 40.9% | Revenue by Segment (Q1 2025 vs Q1 2024) | Segment | Q1 2025 Revenue (EUR million) | Q1 2024 Revenue (EUR million) | Change (%) | | :--- | :--- | :--- | :--- | | **Biopharmaceutical and Diagnostic Solutions** | **220.8** | **198.9** | **11.0%** | | - High-value solutions | 110.3 | 88.0 | 25.4% | | - Other containment and delivery solutions | 110.5 | 111.0 | (0.4)% | | **Engineering** | **35.7** | **37.1** | **(3.5)%** | - Gross profit margin for the Biopharmaceutical and Diagnostic Solutions segment increased to **31.3%** from 27.1% YoY, driven by improvements in new facilities and a higher mix of high-value solutions[199](index=199&type=chunk) - Research and Development expenses decreased by **44.8%** to **€5.9 million**, attributed to cost management, project optimization, and non-recurring severance payments from the prior year[205](index=205&type=chunk)[206](index=206&type=chunk)[207](index=207&type=chunk) [Liquidity and Capital Resources](index=64&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains a solid liquidity position, financing operations through cash flow, debt, and equity, with capital expenditures primarily directed towards capacity expansion in the U.S. and Italy - As of March 31, 2025, the company had cash and cash equivalents of **€90.7 million**[221](index=221&type=chunk) - Capital expenditures for Q1 2025 were **€69.7 million**, with **€64.1 million** dedicated to growth and capacity expansion, mainly for EZ-Fill® production lines in Fishers, Indiana, and Latina, Italy[226](index=226&type=chunk) - In February 2025, the company secured a new **€20.0 million** loan with a five-year tenor to support capital investments in its growth platforms[225](index=225&type=chunk) Cash Flow Summary (Q1 2025) | Metric | Q1 2025 (EUR million) | | :--- | :--- | | Cash flows from operating activities | 99.8 | | Cash flows used in investing activities | (70.7) | | Cash flows used in financing activities | (35.7) | [Key Indicators of Performance and Financial Condition (Non-GAAP)](index=68&type=section&id=Key%20Indicators%20of%20Performance%20and%20Financial%20Condition) The company uses several non-GAAP measures to evaluate performance, with Adjusted EBITDA increasing by 13.4% to €57.4 million and Adjusted Diluted EPS at €0.10 for Q1 2025 Adjusted EBITDA Reconciliation (Q1 2025 vs Q1 2024) | Metric (EUR million) | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net Profit | 26.5 | 18.8 | | (+) Income taxes | 8.6 | 6.9 | | (-) Finance income | (6.0) | (2.7) | | (+) Finance expense | 5.5 | 2.3 | | **Operating Profit** | **34.6** | **25.3** | | (+) Depreciation & amortization | 20.6 | 21.7 | | **EBITDA** | **55.3** | **47.0** | | (+) Adjusting items | 2.1 | 3.6 | | **Adjusted EBITDA** | **57.4** | **50.6** | | **Adjusted EBITDA Margin** | **22.4%** | **21.4%** | Adjusted Operating Profit and Net Profit Reconciliation (Q1 2025) | Metric (EUR million) | Reported | Adjustments | Adjusted | | :--- | :--- | :--- | :--- | | Operating Profit | 34.6 | 2.1 | 36.7 | | Income Taxes | 8.6 | 0.5 | 9.1 | | Net Profit | 26.5 | 1.6 | 28.1 | | Diluted EPS (EUR) | 0.10 | | 0.10 | - Free Cash Flow for Q1 2025 was **€29.7 million**, a significant improvement from a negative €30.6 million in Q1 2024[252](index=252&type=chunk) - Net Debt decreased to **€300.2 million** at March 31, 2025, from €335.0 million at December 31, 2024[254](index=254&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=75&type=section&id=Quantitative%20and%20Qualitative%20Disclosure%20About%20Market%20Risk) The Group is exposed to financial market risks, including foreign currency, interest rate, liquidity, credit, and commodity risks, which are managed through formal hedging policies and central liquidity management - The main financial risks identified are foreign currency exchange rates, interest rates, liquidity, credit, and commodity price fluctuations[259](index=259&type=chunk)[268](index=268&type=chunk) Exchange Rate Sensitivity on Operating Profit | Currency Pair | Change | Effect on Operating Profit (EUR millions) | | :--- | :--- | :--- | | EUR/USD | +5% / -5% | (4.7) / 5.2 | | EUR/MXN | +5% / -5% | (0.6) / 0.6 | | EUR/CNY | +5% / -5% | 0.9 / (1.0) | Interest Rate Sensitivity on Profit Before Tax | Change in Interest Rate | Effect on Profit Before Tax (EUR millions) | | :--- | :--- | | +50 BP | (0.4) | | -50 BP | 0.4 | | +100 BP | (0.8) | | -100 BP | 0.8 | - The Group actively hedges against commodity price volatility for natural gas and electricity using commodity swap contracts[286](index=286&type=chunk)[287](index=287&type=chunk) [Controls and Procedures](index=81&type=section&id=Controls%20and%20Procedures) The company acknowledges material weaknesses in internal control over financial reporting as of December 31, 2024, and is implementing a remediation plan to address these deficiencies - The company's disclosure controls and procedures were deemed not effective as of December 31, 2024, due to previously reported material weaknesses[291](index=291&type=chunk) - A remediation plan is underway to address the material weaknesses, with progress made during Q1 2025, focusing on enhancing financial reporting procedures, internal control awareness, segregation of duties, and IT controls[292](index=292&type=chunk)[293](index=293&type=chunk) [Legal Proceedings](index=82&type=section&id=Legal%20Proceedings) The company is involved in various legal proceedings incidental to its business, but management does not expect a material impact on its financial condition or results of operations - Management does not expect current legal proceedings to have a material impact on the company's business or financial condition[297](index=297&type=chunk) [Risk Factors](index=82&type=section&id=Risk%20Factors) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 20-F for the year ended December 31, 2024 - No material changes have occurred in the risk factors since the filing of the 2024 Annual Report on Form 20-F[298](index=298&type=chunk)

Stevanato Group (STVN) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Lisa Miles - Senior Vice President, Investor RelationsFranco Stevanato - CEO & Chairman of BoardMarco Dal Lago - Chief Financial OfficerPaul Knight - Managing DirectorMichael Ryskin - Managing DirectorDave Windley - Managing DirectorMac Etoch - Senior Research AssociateDoug Schenkel - Managing Director Conference Call Participants Matt Larew - Research Analyst - HealthcareTejas Savant - Executive Director & Senior Hea ...

Stevanato Group (STVN) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good afternoon. This is the Chorus Call conference operator. Welcome and thank you for joining the Stevanato Group First Quarter twenty twenty five Results Conference Call. As a reminder, all participants are in listen only mode. After the presentation, there will be an opportunity to ask questions. At this time, I would like to turn the conference over to Ms. Lisa Miles, Senior Vice President, Investor Relations. Please go ahead ...

Company Performance - Stevanato Group reported quarterly earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of $0.10 per share, and up from $0.09 per share a year ago, representing an earnings surprise of 10% [1] - The company posted revenues of $269.93 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.23%, and an increase from $256.24 million year-over-year [2] - Over the last four quarters, Stevanato has topped consensus revenue estimates four times, but has surpassed consensus EPS estimates only once [2] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - Current consensus EPS estimate for the coming quarter is $0.12 on revenues of $297.06 million, and for the current fiscal year, it is $0.56 on revenues of $1.27 billion [7] - The estimate revisions trend for Stevanato is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Drugs industry, to which Stevanato belongs, is currently in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Stevanato's stock performance [5]